Matches in DBpedia 2014 for { <http://dbpedia.org/resource/AlloMap_molecular_expression_testing> ?p ?o. }
Showing items 1 to 17 of
17
with 100 items per page.
- AlloMap_molecular_expression_testing abstract "AlloMap molecular expression testing, developed and commercialized by XDx, is a gene expression profiling test to identify heart transplant recipients with a low probability of one type of transplant rejection. The test is performed on a blood sample, providing a non-invasive test to help manage the care of patients post transplant. Prior to the availability of this test, the primary method for managing heart transplant rejection was the invasive technique of endomyocardial biopsy.Test results are reported as a single score indicating the probability of moderate/severe acute cellular rejection (ACR). The performance characteristics of the test make it best suited to help indicate that acute cellar rejection is not present. The score is based on the amount of RNA from each gene in a 20-gene panel comprising 11 rejection-related genes and 9 genes used for normalization and quality control. Many of the rejection-related genes are associated with biological pathways involved in the immune response and rejection processes.The test score is used, along with other standard clinical assessments, to evaluate the patient’s probability of acute cellular rejection and the need for additional evaluations. This test is not designed to be informative about other forms of heart rejections such as antibody-mediated rejection (AMR) or cardiac allograft vasculopathy (CAV). AlloMap has been commercially available since 2005 as a CLIA approved Laboratory Developed Test (LDT) and was cleared by the U.S. Food and Drug Administration (FDA) in 2008 as a Class II Medical Device. It is available only from the XDx Reference Laboratory in Brisbane, CA.The use of the test is described in the recommendations for the non-invasive monitoring of acute heart transplant rejection in the first evidence-based clinical practice guidelines for the care of heart transplant recipients issued by the International Society of Heart and Lung Transplantation.".
- AlloMap_molecular_expression_testing wikiPageExternalLink www.allomap.com.
- AlloMap_molecular_expression_testing wikiPageExternalLink www.xdx.com.
- AlloMap_molecular_expression_testing wikiPageID "28667291".
- AlloMap_molecular_expression_testing wikiPageRevisionID "581268836".
- AlloMap_molecular_expression_testing hasPhotoCollection AlloMap_molecular_expression_testing.
- AlloMap_molecular_expression_testing subject Category:Blood_tests.
- AlloMap_molecular_expression_testing subject Category:DNA.
- AlloMap_molecular_expression_testing subject Category:Genomics.
- AlloMap_molecular_expression_testing comment "AlloMap molecular expression testing, developed and commercialized by XDx, is a gene expression profiling test to identify heart transplant recipients with a low probability of one type of transplant rejection. The test is performed on a blood sample, providing a non-invasive test to help manage the care of patients post transplant.".
- AlloMap_molecular_expression_testing label "AlloMap molecular expression testing".
- AlloMap_molecular_expression_testing sameAs m.0cz8h1k.
- AlloMap_molecular_expression_testing sameAs Q4732967.
- AlloMap_molecular_expression_testing sameAs Q4732967.
- AlloMap_molecular_expression_testing wasDerivedFrom AlloMap_molecular_expression_testing?oldid=581268836.
- AlloMap_molecular_expression_testing homepage www.allomap.com.
- AlloMap_molecular_expression_testing isPrimaryTopicOf AlloMap_molecular_expression_testing.